

# **Technology Development Fund**

Monday, May 3, 2021

## Technology & Innovation Development Office (TIDO)

Business Development

Strategic Alliances

Technology Development Fund

Finance & Business Management

Contracts


Patent and Licensing

Maximizing the impact of Boston Children's innovations on patient health while enhancing the research endeavor



## The Development Process & TDF

#### **Pre-Commercialization**



#### **Post-Commercialization**






#### **TDF Mission**

## Translating Innovation into Products to Improve Patient Care

TDF is a seed-stage academic catalyst fund dedicated to translating early-stage, high-impact, commercially promising academic technologies into the independently-validated, later-stage opportunities sought by industry partners and investors.








## **Our Advisors**







Margaret Chu-Moyer Executive Director of Research Amgen



**Anthony Coyle** President & Head, R&D Repertoire Immune Medicines



Alan Crane Entrepreneur Partner Polaris Venture Partners



Skip Fleshman Partner Asset Management Ventures



CSO

PureTech Health

Sandra Glucksmann President & CEO Cedilla Therapeutics



Keith Gottesdiener President & CEO Prime Medicines



Michael Magliochetti Imran Nasrullah Operating Partner Riverside Partners



VP, Head, Open Innovation Ctr Bayer



Entrepreneur in Residence Atlas Ventures



Ken Rhodes SVP, Therapeutics Discovery Wave Life Sciences



Craig Sorensen Former VP. Ext Rsrch & Innov Vertex Pharmaceuticals



**Beverly Teicher** Chief, Molecular Pharmacology National Cancer Institute



Joshua Tolkoff Accelerator Executive CIMIT



**Stacie Weninger Executive Director** F-Prime Biomedical Research



## Industry Feedback & Development Partners

#### **Technical Feasibility**

#### **Market Potential**

#### **Clinical Development**











































SCIENTIFIC



















## 2009-Present

#### 12 fund years completed

#### 444 applications

Vaccines • Therapeutics •
Diagnostics • Devices
Learning tools • Clinical tools
Radiotherapy • Cell Therapy
Drug Delivery • Biologics • Platform





# 108 awards 20 departments/programs 53 Therapeutics • 9 Diagnostics 9 Vaccines • 22 Devices

\$11.8 M allocated \$7.3M Funded

70 Development Grants 26 Pilot Grants









## **Applications & Funded Projects**

#### **Applications / Industry**




#### **Funded projects**






### Successes

Since 2009, BCH has committed \$9M to 85 projects, resulting in...









#### The Grants

# Pilot Grant \$50,000

- Technology unproven
- High potential for intellectual property, but filing may be premature
- Market identified but path undefined
- Additional work necessary to prove the concept and validate the finding

# Development Grant \$150,000


- Technology validated
- Intellectual property protected with at least one filing
- Promising market identified with a defined path
- Additional development necessary for licensing opportunity and value creation



# Eligibility

## **Therapeutics • Vaccines**


## **Devices • Diagnostics**








## **Our Selection Process**





## **Evaluation Criteria**





## 2021 TDF Schedule & Deadlines

May 17 by EOD (5pm)	Letter of Intent Due
July	Applicants receive feedback
August	Full proposal and final presentation slides are due
September	Presentation to the advisory board
November/December	Awards announcement



## **Next Steps**

- Fill out an Invention Disclosure
- 2. Read the TDF Guidelines & Policies
- Download the Letter of Intent (LOI) form
- 4. Submit your LOI via email by May 17, 2021 to technology.development@childrens.harvard.edu



## **Contact Us**

Technology Development Fund <a href="mailto:technology.development@childrens.harvard.edu">technology.development@childrens.harvard.edu</a>
<a href="mailto:https://tinyurl.com/bch-tdf">https://tinyurl.com/bch-tdf</a>

